The Oncosearch | Oncotarget

MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy Research Paper

Maria Rivero, Javier Peinado-Serrano, Sandra MuÃ±oz-Galvan, Asuncion Espinosa-SÃ¡nchez, Elisa Suarez-Martinez, Blanca Felipe-Abrio, Maria Carmen FernÃ¡ndez-FernÃ¡ndez, Maria Jose Ortiz, Amancio Carnero

Published Aug 31, 2018 · Vol. 9, No. 68 · pp. 32958-32971

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition Research Paper

Rania El Botty, Florence Coussy, Rana Hatem, Franck Assayag, Sophie Chateau-Joubert, Jean-Luc Servely, Sophie Leboucher, Charles Fouillade, Sophie Vacher, BÃ©rengÃ¨re Ouine, AurÃ©lie Cartier, Leanne de Koning, Paul Cottu, Ivan BiÃ¨che, Elisabetta Marangoni

Published Jul 3, 2018 · Vol. 9, No. 51 · pp. 29587-29600

Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells Research Paper

Vojtech Novohradsky, Juraj Zajac, Oldrich Vrana, Jana Kasparkova, Viktor Brabec

Published Jun 19, 2018 · Vol. 9, No. 47 · pp. 28456-28473

The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors Research Paper

Elizaveta E. Alemasova, Konstantin N. Naumenko, Tatyana A. Kurgina, Rashid O. Anarbaev, Olga I. Lavrik

Published May 4, 2018 · Vol. 9, No. 34 · pp. 23349-23365

Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus Research Perspective

Ettore Capoluongo, Giovanni Scambia, Jean-Marc Nabholtz

Published Apr 13, 2018 · Vol. 9, No. 28 · pp. 19463-19468

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models Research Paper

Francesca Vena, Ruochen Jia, Arman Esfandiari, Juan J. Garcia-Gomez, Manuel Rodriguez-Justo, Jianguo Ma, Sakeena Syed, Lindsey Crowley, Brian Elenbaas, Samantha Goodstal, John A. Hartley, Daniel Hochhauser

Published Jan 22, 2018 · Vol. 9, No. 14 · pp. 11592-11603

Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells Research Paper

Benigno C. Valdez, Yang Li, David Murray, Yan Liu, Yago Nieto, Richard E. Champlin, Borje S. Andersson

Published Dec 17, 2017 · Vol. 9, No. 3 · pp. 3908-3921

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer Research Paper

Ethan Brill, Takuhei Yokoyama, Jayakumar Nair, Minshu Yu, Yeong-Ran Ahn, Jung-Min Lee

Published Oct 31, 2017 · Vol. 8, No. 67 · pp. 111026-111040

Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines Research Paper

Frank Ziemann, Steve Seltzsam, Kristin Dreffke, Stefanie Preising, Andrea Arenz, Florentine S.B. Subtil, Thorsten Rieckmann, Rita Engenhart-Cabillic, Ekkehard Dikomey, Andrea Wittig

Published Oct 24, 2017 · Vol. 8, No. 62 · pp. 105170-105183

PARP inhibition causes premature loss of cohesion in cancer cells Research Paper

Eva Kukolj, Tanja Kaufmann, Amalie E. Dick, Robert Zeillinger, Daniel W. Gerlich, Dea Slade

Published Oct 16, 2017 · Vol. 8, No. 61 · pp. 103931-103951

CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents Priority Research Paper

Hongwei Liao, Fang Ji, Xinwei Geng, Meichun Xing, Wen Li, Zhihua Chen, Huahao Shen, Songmin Ying

Published Oct 10, 2017 · Vol. 8, No. 53 · pp. 90662-90673

RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells Research Paper

Ye Zhang, Xiao-Hong Liao, Hong-Yan Xie, Zhi-Min Shao, Da-Qiang Li

Published Oct 10, 2017 · Vol. 8, No. 55 · pp. 94505-94518

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model Research Paper

Gerben R. Borst, Ramya Kumareswaran, Hatice YÃ¼cel, Seyda Telli, Trevor Do, Trevor McKee, Gaetano Zafarana, Jos Jonkers, Marcel Verheij, Mark J. Oâ€™Connor, Sven Rottenberg, Robert G. Bristow

Published Sep 15, 2017 · Vol. 8, No. 50 · pp. 87638-87646

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib Research Paper

Atsushi Osoegawa, Joell J. Gills, Shigeru Kawabata, Phillip A. Dennis

Published Jul 28, 2017 · Vol. 8, No. 50 · pp. 87044-87053

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin Correction

JosÃ© Luis OrdÃ³Ã±ez, Ana Teresa Amaral, Angel M. Carcaboso, David Herrero-MartÃn, MarÃa del Carmen GarcÃa-MacÃas, Vicky Sevillano, Diego Alonso, Guillem Pascual-Pasto, Laura San-Segundo, Monica Vila-Ubach, Telmo Rodrigues, Susana Fraile, Cristina Teodosio, AgustÃn Mayo-Iscar, Miguel Aracil, Carlos MarÃa Galmarini, Oscar M. Tirado, Jaume Mora, Enrique de Ãlava

Published Jun 27, 2017 · Vol. 8, No. 26 · pp. 43592-43592

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice Priority Research Paper

Jolien S. de Groot, Paul J. van Diest, Miranda van Amersfoort, Eva J. Vlug, Xiaojuan Pan, Natalie D. ter Hoeve, Hilde Rosing, Jos H. Beijnen, Sameh A. Youssef, Alain de Bruin, Jos Jonkers, Elsken van der Wall, Patrick W.B. Derksen

Published Jun 15, 2017 · Vol. 8, No. 37 · pp. 60750-60763

Olaparib and somatic BRCA mutations News

Angela George, Susana Banerjee, Stan Kaye

Published Jun 8, 2017 · Vol. 8, No. 27 · pp. 43598-43599

mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer Research Paper

Tetsuo Mashima, Yoko Taneda, Myung-Kyu Jang, Anna Mizutani, Yukiko Muramatsu, Haruka Yoshida, Ayana Sato, Noritaka Tanaka, Yoshikazu Sugimoto, and Hiroyuki Seimiya

Published May 24, 2017 · Vol. 8, No. 29 · pp. 47902-47915

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting Priority Research Paper

Brian A. Dougherty, Zhongwu Lai, Darren R. Hodgson, Maria C.M. Orr, Matthew Hawryluk, James Sun, Roman Yelensky, Stuart K. Spencer, Jane D. Robertson, Tony W. Ho, Anitra Fielding, Jonathan A. Ledermann, J. Carl Barrett

Published May 4, 2017 · Vol. 8, No. 27 · pp. 43653-43661

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer Research Paper

Mark Yarchoan, Melinda C. Myzak, Burles A. Johnson III, Ana De Jesus-Acosta, Dung T. Le, Elizabeth M. Jaffee, Nilofer S. Azad, Ross C. Donehower, Lei Zheng, Paul E. Oberstein, Robert L. Fine, Daniel A. Laheru, Michael Goggins

Published Apr 19, 2017 · Vol. 8, No. 27 · pp. 44073-44081

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy Research Paper

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition Research Paper

Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells Research Paper

The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors Research Paper

Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus Research Perspective

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models Research Paper

Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells Research Paper

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer Research Paper

Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines Research Paper

PARP inhibition causes premature loss of cohesion in cancer cells Research Paper

CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents Priority Research Paper

RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells Research Paper

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model Research Paper

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib Research Paper

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin Correction

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice Priority Research Paper

Olaparib and somatic BRCA mutations News

mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer Research Paper

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting Priority Research Paper

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy Research Paper

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition Research Paper

Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells Research Paper

The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors Research Paper

Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus Research Perspective

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models Research Paper

Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells Research Paper

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer Research Paper

Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines Research Paper

PARP inhibition causes premature loss of cohesion in cancer cells Research Paper

CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents Priority Research Paper

RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells Research Paper

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model Research Paper

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib Research Paper

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin Correction

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice Priority Research Paper

Olaparib and somatic BRCA mutations News

mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer Research Paper

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting Priority Research Paper

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer Research Paper